<h3>享受 TipRanks 高级版 50% 折扣，放心投资</h3>
<ul>
<li>解锁对冲基金级别的数据和强大的投资工具，帮助您做出更聪明、更精准的决策</li>
<li>通过最新的新闻和分析保持市场领先，使您的投资组合始终处于最大潜力的状态</li>
</ul>
<p>Theriva Biologics ( (TOVX) ) 发布了公告。</p>
<p>2025 年 12 月 15 日，Theriva Biologics 未能召开特别股东会议，因为缺乏足够的股份以构成法定人数。因此，公司将重新安排会议，以寻求对根据与机构投资者签订的认股权证诱导协议所需的认股权证行使提案的批准。该协议要求 Theriva Biologics 每 60 天召开一次股东会议，直到获得批准或认股权证不再有效。</p>
<p>对 (TOVX) 股票的最新分析师评级为买入，目标价为 7.00 美元。要查看关于 Theriva Biologics 股票的完整分析师预测列表，请参见 TOVX 股票预测页面。</p>
<p><strong>Spark 对 TOVX 股票的看法</strong></p>
<p>根据 Spark，TipRanks 的 AI 分析师，TOVX 的评级为中性。</p>
<p>Theriva Biologics 面临重大财务困难，收入为零且亏损不断扩大，这令人担忧。尽管技术指标显示出一些短期的积极动能，但长期趋势仍然是负面的。缺乏盈利能力影响了估值。然而，最近的积极临床试验结果提供了一个潜在的未来催化剂，可能改善公司的前景。</p>
<p>要查看 Spark 对 TOVX 股票的完整报告，请点击这里。</p>
<p><strong>关于 Theriva Biologics 的更多信息</strong></p>
<p>Theriva Biologics, Inc. 在生物技术行业运营，专注于生物治疗的开发。该公司致力于创造创新解决方案，以满足未满足的医疗需求，市场重点在于推进治疗选择。</p>
<p><strong>平均交易量：</strong> 15,391,171</p>
<p><strong>技术情绪信号：</strong> 强烈卖出</p>
<p><strong>当前市值：</strong> 733 万美元</p>
<p>在 TipRanks 的股票分析页面上找到 TOVX 股票的详细分析。</p>

TOVX

<p>Theriva Biologics 已因缺乏足够的股份而重新安排特别股东会议。此次会议旨在寻求对与机构投资者达成的协议下的认股权证行使提案的批准。公司必须每 60 天继续召开会议，直到获得批准。Theriva Biologics 面临财务挑战，收入为零且亏损不断扩大，但最近积极的临床试验结果提供了未来潜在的催化剂。该股票被评级为买入，目标价为 7.00 美元，尽管技术情绪被评为强烈卖出</p>

<h3>Claim 50% Off TipRanks Premium and Invest with Confidence</h3>
<div class="lb-trans"><h3>享受 TipRanks 高级版 50% 折扣，放心投资</h3>
</div><ul>
<li>Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions</li>
<li>Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁对冲基金级别的数据和强大的投资工具，帮助您做出更聪明、更精准的决策</li>
<li>通过最新的新闻和分析保持市场领先，使您的投资组合始终处于最大潜力的状态</li>
</ul>
</div><p>Theriva Biologics ( (TOVX) ) has provided an announcement.</p>
<div class="lb-trans"><p>Theriva Biologics ( (TOVX) ) 发布了公告。</p>
</div><p>On December 15, 2025, Theriva Biologics was unable to convene its Special Meeting of Stockholders due to insufficient shares present to constitute a quorum. Consequently, the company will reschedule the meeting to seek approval for a warrant exercise proposal, as required under a warrant inducement agreement with institutional investors. This agreement mandates that Theriva Biologics continues to call stockholder meetings every 60 days until approval is obtained or the warrants are no longer outstanding.</p>
<div class="lb-trans"><p>2025 年 12 月 15 日，Theriva Biologics 未能召开特别股东会议，因为缺乏足够的股份以构成法定人数。因此，公司将重新安排会议，以寻求对根据与机构投资者签订的认股权证诱导协议所需的认股权证行使提案的批准。该协议要求 Theriva Biologics 每 60 天召开一次股东会议，直到获得批准或认股权证不再有效。</p>
</div><p>The most recent analyst rating on (TOVX) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Theriva Biologics stock, see the TOVX Stock Forecast page.</p>
<div class="lb-trans"><p>对 (TOVX) 股票的最新分析师评级为买入，目标价为 7.00 美元。要查看关于 Theriva Biologics 股票的完整分析师预测列表，请参见 TOVX 股票预测页面。</p>
</div><p><strong>Spark’s Take on TOVX Stock</strong></p>
<div class="lb-trans"><p><strong>Spark 对 TOVX 股票的看法</strong></p>
</div><p>According to Spark, TipRanks’ AI Analyst, TOVX is a Neutral.</p>
<div class="lb-trans"><p>根据 Spark，TipRanks 的 AI 分析师，TOVX 的评级为中性。</p>
</div><p>Theriva Biologics faces substantial financial difficulties with no revenue and growing losses, which is a major concern. While technical indicators show some short-term positive momentum, the long-term trend remains negative. The lack of profitability impacts valuation. However, the recent positive clinical trial results provide a potential future catalyst that could improve the company’s prospects.</p>
<div class="lb-trans"><p>Theriva Biologics 面临重大财务困难，收入为零且亏损不断扩大，这令人担忧。尽管技术指标显示出一些短期的积极动能，但长期趋势仍然是负面的。缺乏盈利能力影响了估值。然而，最近的积极临床试验结果提供了一个潜在的未来催化剂，可能改善公司的前景。</p>
</div><p>To see Spark’s full report on TOVX stock, click here.</p>
<div class="lb-trans"><p>要查看 Spark 对 TOVX 股票的完整报告，请点击这里。</p>
</div><p><strong>More about Theriva Biologics</strong></p>
<div class="lb-trans"><p><strong>关于 Theriva Biologics 的更多信息</strong></p>
</div><p>Theriva Biologics, Inc. operates in the biotechnology industry, focusing on the development of biologic therapies. The company is involved in creating innovative solutions to address unmet medical needs, with a market focus on advancing therapeutic options.</p>
<div class="lb-trans"><p>Theriva Biologics, Inc. 在生物技术行业运营，专注于生物治疗的开发。该公司致力于创造创新解决方案，以满足未满足的医疗需求，市场重点在于推进治疗选择。</p>
</div><p><strong>Average Trading Volume:</strong> 15,391,171</p>
<div class="lb-trans"><p><strong>平均交易量：</strong> 15,391,171</p>
</div><p><strong>Technical Sentiment Signal:</strong> Strong Sell</p>
<div class="lb-trans"><p><strong>技术情绪信号：</strong> 强烈卖出</p>
</div><p><strong>Current Market Cap:</strong> $7.33M</p>
<div class="lb-trans"><p><strong>当前市值：</strong> 733 万美元</p>
</div><p>Find detailed analytics on TOVX stock on TipRanks’ Stock Analysis page.</p>
<div class="lb-trans"><p>在 TipRanks 的股票分析页面上找到 TOVX 股票的详细分析。</p>
</div>

Theriva Biologics 重新安排特别股东大会